Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II intratumoral L19IL2 + L19TNF in non-melanoma skin cancer
2020-003299-42Phase 2Active
- Sponsor
- Philogen
- Start
- Nov 2020
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darleukin and onfekafusp alfa in basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC) and non-melanoma skin cancer (NMSC), sponsored by Philogen. Primary endpoint: Confirmed Best Overall Response Rate for basal cell carcinoma. Started Nov 2020; status: active.
02
Drugs
darleukinonfekafusp alfa
03
Conditions
basal cell carcinoma (BCC)cutaneous squamous cell carcinoma (cSCC)non-melanoma skin cancer (NMSC)
Beyond the preview
Go deeper on 2020-003299-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003299-42.